Actively Recruiting
Non-Inferiority Study Comparing Hysteroscopic Repeat Curettage and Methotrexate Chemotherapy for Low-risk Postmolar Gestational Trophoblastic Neoplasia
Led by Women's Hospital School Of Medicine Zhejiang University · Updated on 2026-10-21
70
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial focuses on low-risk postmolar gestational trophoblastic neoplasia GTN, a type of malignant tumor originating from placental cells, mostly following hydatidiform mole pregnancies. Researchers are evaluating whether hysteroscopic repeat curettage can be used as a first-line treatment compared with the classic single-agent methotrexate chemotherapy. The goal is to find a treatment approach that maintains effectiveness while reducing chemotherapy-related side effects and improving quality of life. Participants are randomly assigned to one of two groups one receiving methotrexate injections at 0.4mgkg daily for 5 days every two weeks, and the other undergoing hysteroscopic repeat curettage surgery. This prospective, multicenter study uses a crossover design to compare the treatments safety, effectiveness, and impact on ovarian function, pregnancy rates, and menstrual cycle resumption over two years. During the study, participants will be monitored for tumor response, adverse events, and complications related to surgery or chemotherapy. Researchers will assess complete response rates, chemotherapy-sparing effects, survival, and reproductive outcomes. The study involves regular follow-ups and laboratory tests to track health, treatment effects, and quality of life for up to two years after treatment initiation.
CONDITIONS
Brief Title
Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here